Adjuvant therapy of Stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy Academic Article uri icon

Overview

MeSH Major

  • Adjuvants, Pharmaceutic
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Mastectomy, Segmental
  • Radiotherapy

abstract

  • A pilot study was undertaken to assess the feasibility, toxicity, and efficacy of combined radiation therapy and chemotherapy in the adjuvant treatment of node-positive. Stage II patients with breast carcinoma who had undergone lumpectomy. Therapy consisted of three phases, starting with a six-week CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone) induction, followed by radiation therapy to the breast, and concluding with four cycles of VATH (vinblastine, Adriamycin, thiotepa, Halotesin). Twenty-seven patients were entered with an average age of 51.5 years (median 50 yrs) and a mean follow-up of 46.2 months. Twenty-three patients (85.2%) are alive and 19 (70.3%) disease free. There were no ipsilateral local recurrences. Cosmetic results were good to excellent in 26/27 patients. The doses of VATH were not compromised by the prior therapy. The regimen was found to be tolerable and is a reasonable approach in the adjuvant treatment of this particular patient population.

publication date

  • January 1991

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 1907428

Additional Document Info

start page

  • 317

end page

  • 21

volume

  • 14

number

  • 4